COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT
Completed
National University Hospital, Singapore
Phase 2/Phase 3
2007-08-01
This is a randomised controlled trial to investigate the efficacy of preventive regimen of
hydration with high dose oral N-acetylcysteine and intravenous sodium bicarbonate
pretreatment in patients with stable advanced renal insufficiency (CKD stage 3 and 4:GFR
15-60ml/min/1.73m2 calculated by Modification of Diet in Renal Disease Study equation (MDRD
formula)) undergoing elective percutaneous coronary intervention (PCI).
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
Terminated
Guerbet
Phase 4
2009-01-01
The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in
subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed
tomography.
Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography
Terminated
Mallinckrodt
Phase 4
2009-01-01
The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in
subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed
tomography.
Endoscopic retrograde cholangiopancreatography (ERCP) is now a widely accepted therapy for
treating benign and malignant diseases of the pancreatobiliary tree. Acute pancreatitis
represents the most common and feared complication following ERCP. The reported incidence of
this complication is from 1% to 40% according to the presence of high-risk factors for this
complication or the presence dysfunction in the sphincter of Oddi (SOD). In most prospective
series, the incidence has ranged between 3.5% and 20% for nonselected and high-risk patients,
respectively. Independent risk factors for post-ERCP pancreatitis are either patient- or
procedure-related.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
